Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Change in Cash came in at -$88.7 million in Q1 2026, up 5.46% YoY from -$84.1 million in Q1 2025, and down 202.26% on a QoQ basis from $86.8 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Change in Cash data on file, last reported at -$88.7 million in Q1 2026.
- Quarterly Change in Cash rose 5.46% year-over-year to -$88.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.0 million (down 23.14% YoY) and the FY2025 annual result came in at $150.9 million, down 25.15% from the prior year.
- Change in Cash eased to -$88.7 million in Q1 2026, from $86.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $222.8 million in Q1 2022 to a low of -$95.3 million in Q1 2024.
- A 5-year average of $21.8 million and a median of $780000.0 in 2022 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2023 — Change in Cash sank 2615.0% — and 2024, when it soared 3863.8%.
- Tracing RXRX's Change in Cash over 5 years: stood at $94.2 million in 2022, then tumbled by 95.52% to $4.2 million in 2023, then soared by 3863.8% to $167.2 million in 2024, then slumped by 48.1% to $86.8 million in 2025, then slumped by 202.26% to -$88.7 million in 2026.
- The last three Change in Cash figures came in at -$88.7 million (Q1 2026), $86.8 million (Q4 2025), and $133.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -108.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -108.36 Mn |
| Mar 31, 2026 | -88.74 Mn |
| Dec 31, 2025 | 86.78 Mn |
| Sep 30, 2025 | 133.30 Mn |
| Jun 30, 2025 | 24.69 Mn |
| Mar 31, 2025 | -93.87 Mn |
| Dec 31, 2024 | 167.19 Mn |
| Sep 30, 2024 | -46.92 Mn |
| Jun 30, 2024 | 176.60 Mn |
| Mar 31, 2024 | -95.28 Mn |
| Dec 31, 2023 | 4.22 Mn |
| Sep 30, 2023 | -19.62 Mn |
| Jun 30, 2023 | -65.55 Mn |
| Mar 31, 2023 | -76.73 Mn |
| Dec 31, 2022 | 94.22 Mn |
| Sep 30, 2022 | 780,000.00 |
| Jun 30, 2022 | -54.02 Mn |
| Mar 31, 2022 | 222.78 Mn |
| Dec 31, 2021 | -109.61 Mn |
| Sep 30, 2021 | -238.02 Mn |